BofA reiterates Underperform on ConAgra stock, $15 target on CEO change

BofA Securities reiterated an Underperform rating and $15 price target on ConAgra, citing leadership-transition uncertainty, inflation pressure on fiscal 2026 EPS, and risk to fiscal 2027 growth. The firm also flagged an elevated dividend payout ratio above 80% versus a 50-55% target and 3.8x net debt/EBITDA leverage, although the stock already trades near its 52-week low of $15.04 with a 9.2% yield. UBS and Stifel also lowered targets to $16 and $17, respectively, after ConAgra posted $0.39 EPS, missing consensus by $0.01 despite 2.4% organic sales growth.

Analysis

CAG looks less like a clean turnaround and more like a balance-sheet repair story with an operational overhang. A leadership change can help on execution, but the market is effectively paying for a high-yield equity with little room for error: when leverage is still elevated and payout policy is above a sustainable range, every incremental margin miss forces a choice between dividend integrity and deleveraging. That tends to compress the multiple before it improves fundamentals, because income holders usually sell first and re-enter only after the payout is de-risked.

The second-order read-through is to peers in packaged food: if ConAgra is forced to monetize assets, it could become a marginal seller of brands at suboptimal valuations, which is a sign that private-market exits in staples remain open but public-market equity value is not. SJM is the cleaner relative long if investors want exposure to a more credible operating trajectory; CAG’s issues are more balance-sheet and governance-driven, which means the catalyst path is slower and more binary over 6-18 months. UBS/Stifel cuts likely frame the near-term consensus reset, but the next leg lower would require another guidance cut or explicit dividend-risk language.

The contrarian angle is that the stock may already be pricing a stress case that is closer to a cyclical trough than a permanent impairment. If inflation moderates and Brase can extract even modest mix/margin improvement, the high yield can act as a floor and attract event-driven capital. The key is timing: the next 1-2 quarters are about proving stabilization; the 12-month question is whether capital allocation shifts from income defense to de-leveraging, which would be the real rerating trigger.

Key Decisions for Investors

• Short CAG on rallies into the high-teens, 3-6 month horizon; risk/reward favors downside if the market begins to price dividend restraint or another guidance reset.
• Structure a CAG put spread (e.g., 6-9 month tenor) to express dividend/deleveraging risk with limited premium outlay; best if implied vol stays below realized catalysts.
• Relative-value: long SJM / short CAG over 3-6 months; SJM has a cleaner execution narrative while CAG carries higher balance-sheet and payout-policy risk.
• For income-focused accounts, avoid chasing the 9% yield until management explicitly commits to a lower payout ratio or asset-sale path; the yield is more likely to be a value trap than a floor in the near term.
• Watch for a tactical long only after two signs: no further EPS/guidance cuts and evidence of deleveraging or dividend normalization; otherwise the stock remains a sell-the-bounce name.